As healthcare moves to an outcomes-based model, Pharma is starting to accept the idea of contracts that tie reimbursement for therapies to patient outcomes
Is the outcomes based contract agreed for Kymriah the beginning of a trend? The one-time drug has a hefty price tag of $475,000, but Novartis will only receive payment from CMS if patients show significant improvement. Are these contracts a good way of sharing risk and ensuring wider access to novel therapies?
Gene cell therapy, biologics, and other complicated treatments are the wave of the future — where Medical Affairs plays an increasingly important role
If the drug gains full FDA approval in January 2018, it will be the first ever gene cell therapy approved for an inherited disease.
KOL as a term isn’t going anywhere anytime soon. That was the takeaway from a recent Medical Science Liaison Society and the term is taking on other meanings as well